Category: News & Comments

Johnson & Johnson COVID-19 Vaccine Voting Tomorrow with Expected Approval on Saturday

Johnson & Johnson COVID-19 Vaccine According to a new analysis posted online by the FDA, the Johnson & Johnson ( JNJ ) vaccine is providing strong protection against severe disease and death related to COVID-19 infection. The vaccine may reduce...

Read More

February 25, 2021

0

Eisai and Biogen: Lecanemab for the Treament of Early Alzheimer's DIisease

Eisai and Biogen Inc: Lecanemab Eisai  and Biogen Inc. ( BIIB ) announced that Eisai has completed the rolling submission to the U.S. FDA of a Biologics License Application ( BLA ) under the accelerated approval pathway for the investigational...

Read More

May 10, 2022

0

XyloCor Therapeutics Reported Positive Safety and Efficacy Results of XC001 Novel Gene Therapy for Refractory Angina

XyloCor Therapeutics Announced Positive Results for XC001 XyloCor Therapeutics announced the completion of the Phase 2 portion of its Phase 1/2 clinical trial ( EXACT ) designed to assess the safety and preliminary evidence of efficacy of lead gene therapy candidate XC001...

Read More

January 27, 2023

0

An Important Reminder from Vir Biotechnology

Vir Biotechnology  Vir Biotechnology ( VIR ) is a commercial-stage immunology firm focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir assembled four technology platforms that stimulate and enhance the immune system by exploiting...

Read More

May 19, 2022

0

Aveo Oncology: The FDA Approved FOTIVDA for Adults with Relapsed or Refractory Advanced RCC

Aveo Oncology Received FDA Approval for FOTIVDA for Advanced RCC Aveo Oncology ( AVEO ) drug FOTIVDA is an oral, next-generation vascular endothelial growth factor ( VEGF ) tyrosine kinase inhibitor ( TKI ). It is a potent, selective inhibitor...

Read More

March 11, 2021

0

Vertex Pharmaceuticals and Type 1 Diabetes

Vertex Pharmaceuticals to Announce New Data on VX-880 Clinical Trial Vertex Pharmaceuticals ( VRTX ) announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes ( T1D ) and its Phase 1/2 trial of...

Read More

May 31, 2022

0

Immutep Ltd: Evaluating the Safety and Efficacy of Eftilagimod Alpha in Combination with Merck's KEYTRUDA

Immutep Ltd and Merck Announce Second Clinical Trial Collaboration Immutep ( IMMP ) develops novel immunotherapy treatments for cancer, infectious disease and autoimmune diseases. Today, Immutep announced a second clinical trial collaboration and supply agreement with Merck & Co (...

Read More

March 16, 2021

0

As Expected, Seagen Was Taken Over, the Buyer is Pfizer.

Pfizer to Acquire Seagen Pfizer ( PFE ) is to acquire Seagen ( SGEN ) for $229 per share in cash, for a total enterprise value of approximately $43 billion Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer, said,...

Read More

March 13, 2023

0

23andMe Teams Up with Novartis on Lipoprotein(a) Education for its Customers

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease March 24, 2023 (GLOBE NEWSWIRE) -- In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. ( ME ) announced a collaboration with Novartis Pharmaceuticals Corporation...

Read More

March 24, 2023

0

Novartis Announced Positive Results of Phase 3 Study Using 177Lu-PSMA-617 in Advanced Prostate Cancer Patients

Novartis Positive Results for Radioligand Therapy, 177Lu-PSMA-617, for mCRPC Novartis ( NVS ) reported the first interpretable results of evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy, in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (...

Read More

March 24, 2021

0

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0